Isogenica Limited Announces Latest Board Level Appointment
CAMBRIDGE, England--(BUSINESS WIRE)--Isogenica today announced the appointment of Göran Forsberg to the Board of Directors.
Currently Chief Business Officer (CBO) at Active Biotech in Lund, Sweden, Göran brings extensive industry experience to Isogenica. He holds a Ph.D. in Biochemistry from the Royal Institute of Technology, Stockholm, Sweden and has authored approximately 40 scientific articles primarily within biochemistry, molecular biology, immunology and cancer research. Göran has worked in the pharmaceutical industry for almost 25 years as a scientist, project leader or department head within KabiGen, Pharmacia and the University of Adelaide. Since 2008, he has been responsible for business development at Active Biotech, a company developing new products for the treatment of autoimmune diseases and cancer with three products in pivotal clinical studies.
Currently Chief Business Officer (CBO) at Active Biotech in Lund, Sweden, Göran brings extensive industry experience to Isogenica. He holds a Ph.D. in Biochemistry from the Royal Institute of Technology, Stockholm, Sweden and has authored approximately 40 scientific articles primarily within biochemistry, molecular biology, immunology and cancer research. Göran has worked in the pharmaceutical industry for almost 25 years as a scientist, project leader or department head within KabiGen, Pharmacia and the University of Adelaide. Since 2008, he has been responsible for business development at Active Biotech, a company developing new products for the treatment of autoimmune diseases and cancer with three products in pivotal clinical studies.